文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

女性生殖道肿瘤的姑息性放疗:结局与预后因素

Palliative radiotherapy in cancers of female genital tract: Outcomes and prognostic factors.
PubMed 文献 · Radiother Oncol · 2022-08-11

该研究汇总英国两家大型中心2013至2018年间接受至少1次盆腔姑息性放疗的晚期女性生殖道肿瘤患者数据,共184例可评估疗效与毒性,165例有生存数据。放疗前症状的主观缓解率为80.4%,3级及以上胃肠道、泌尿及其他毒性发生率分别为2.2%、3.8%和2.7%。处方EQD2₁₀与症状控制或毒性均无统计学显著相关性,1年总生存率为25.1%(中位5.9个月)。

要点

  • 晚期女性生殖道肿瘤姑息性放疗的症状主观缓解率为80.4%,3级及以上毒性发生率低。
  • 处方EQD2₁₀与症状控制或毒性无统计学显著相关性,支持采用短程低剂量姑息放疗方案。
  • 无远处转移、完成计划放疗疗程、对放疗有反应及接受后续治疗为独立预后因素。

核心结论

  • 姑息性放疗对晚期女性生殖道肿瘤的症状有效且毒性低。
  • 处方EQD2₁₀与症状控制或毒性无统计学显著相关性,支持采用短程低剂量姑息性放疗方案。

研究设计与样本

  • 汇总英国两家大型中心的数据进行分析。
  • 纳入2013年至2018年间接受至少1次盆腔姑息性放疗的晚期女性生殖道肿瘤患者。
  • 收集人口学与肿瘤资料、放疗剂量分割及既往和后续治疗详情。
  • 疗效以毒性、症状缓解和生存定义;合并症采用改良ACE 27评分记录,该评分在所有患者中针对未控制的女性生殖道肿瘤进行了调整。
  • 共184例患者纳入治疗反应与毒性分析,165例患者有生存数据。

主要发现

  • 放疗前症状的主观缓解记录于80.4%的患者。
  • 3级或更差的胃肠道、泌尿及其他(呕吐、乏力、疼痛)毒性发生率分别为2.2%、3.8%和2.7%。
  • 处方EQD2₁₀与症状控制或毒性之间未见统计学显著相关性。
  • 1年总生存率为25.1%(中位5.9个月)。
  • 无远处转移、完成计划放疗疗程、对放疗有反应及接受后续治疗为独立预后因素。

关键数值与推荐

  • 放疗前症状的主观缓解率为80.4%。
  • 3级或更差胃肠道毒性发生率为2.2%。
  • 3级或更差泌尿毒性发生率为3.8%。
  • 3级或更差其他(呕吐、乏力、疼痛)毒性发生率为2.7%。
  • 1年总生存率为25.1%,中位生存5.9个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Metastatic and incurable cancers of the gynaecological tract (FGTC) represent a major global health burden. Systemic treatment has modest efficacy and radiotherapy is often used for local symptoms. This study combines experience from two large UK centres in palliative radiotherapy for gynaecological cancers. MATERIALS AND METHODS: Pooled data from two major centres was analysed. Advanced FGTC patients who received at least one fraction of palliative radiotherapy to the pelvis between 2013 and 2018 were included. Data collected included demographic and tumour details, radiotherapy dose fractionation and details of previous and subsequent treatment. Response was defined in terms of toxicity, symptomatic response and survival. Comorbidities were recorded using a modified ACE 27 score which is adjusted for the presence of uncontrolled FGTC in all the patients. RESULTS: A total of 184 patients were included for treatment response and toxicity; survival data was available for 165 patients. Subjective response in pre-radiotherapy symptoms was documented in 80.4%. Grade 3 or worse gastrointestinal, urinary and other (vomiting, fatigue, pain) toxicity incidence was 2.2%, 3.8%, and 2.7% respectively. No statistically significant correlation between the prescribed EQD210 and symptom control or toxicity was seen. 1 year overall survival was 25.1% (median 5.9 months). Absent distant metastases, completion of the intended course of radiotherapy, response to radiotherapy, and receipt of further lines of treatment were independent prognostic factors. CONCLUSION: Palliative radiotherapy is effective for symptoms of advanced FGTC with low toxicity. The absence of a dose response argues for short low dose palliative radiotherapy schedules to be used.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kombathula SH, Cree A, Joshi PV, et al. Palliative radiotherapy in cancers of female genital tract: Outcomes and prognostic factors. Radiother Oncol. 2022. PMID: 35964765. doi:10.1016/j.radonc.2022.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。